For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the emergence of this treatment and Attruby represents a true change. These groundbreaking therapies stabilize the transthyretin protein, halting its destructive build-up and alleviating the burden